These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12901324)

  • 1. Reduced-intensity allogeneic stem cell transplantation.
    Bearman SI
    Curr Hematol Rep; 2003 Jul; 2(4):277-86. PubMed ID: 12901324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
    Belkacémi Y; Labopin M; Hennequin C; Hoffstetter S; Mungai R; Wygoda M; Lundell M; Finke J; Aktinson C; Lorchel F; Durdux C; Basara N
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):544-51. PubMed ID: 17141976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
    Rowley SD; Goldberg SL; Pecora AL; Hsu JS; Brecher BA; Butrin L; Kobbe K; McKiernan P; Preti R
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):784-93. PubMed ID: 15505609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia.
    Al-Ali H; Cross M; Lange T; Freund M; Dölken G; Niederwieser D
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S17-22. PubMed ID: 19561407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
    Banna GL; Aversa S; Sileni VC; Favaretto A; Ghiotto C; Monfardini S
    Crit Rev Oncol Hematol; 2004 Sep; 51(3):171-89. PubMed ID: 15331077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
    Giralt S
    Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
    Chan GW; Foss FM; Klein AK; Sprague K; Miller KB
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):753-9. PubMed ID: 14677114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Lekakis L; de Lima M
    Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia.
    Carella AM; Giralt S; Slavin S
    Haematologica; 2000 Mar; 85(3):304-13. PubMed ID: 10702821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
    Kusumi E; Kami M; Yuji K; Hamaki T; Murashige N; Hori A; Kojima R; Kishi Y; Kim SW; Ueyama J; Miyakoshi S; Tanosaki R; Morinaga S; Mori S; Heike Y; Muto Y; Masuo S; Taniguchi S; Takaue Y
    Bone Marrow Transplant; 2004 Apr; 33(7):697-702. PubMed ID: 14755317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies.
    Sureda A; Schmitz N
    Ann Hematol; 2003 Jan; 82(1):1-13. PubMed ID: 12574957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model.
    Vanclée A; Lutgens LC; Oving EB; Deutz NE; Gijbels MJ; Schouten HC; Bos GM
    Bone Marrow Transplant; 2005 Nov; 36(10):907-15. PubMed ID: 16151417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.